Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. View (RXRX) real-time stock price, chart, news, analysis, analyst reviews and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback